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ABSTRACT
Sphingosine 1-phosphate (S1P) is a bioactive lipid that is formed by the 
phosphorylation of sphingosine and catalysed by sphingosine kinase 1 (SK1) or 
sphingosine kinase 2 (SK2). Sphingosine kinases play a fundamental role in many 
signaling pathways associated with cancer, suggesting that proteins belonging to this 
signaling network represent potential therapeutic targets. Over the last years, many 
improvements have been made in the treatment of T-cell acute lymphoblastic leukemia 
(T-ALL); however, novel and less toxic therapies are still needed, especially for 
relapsing and chemo-resistant patients. Here, we analyzed the therapeutic potential 
of SKi and ROMe, a sphingosine kinase 1 and 2 inhibitor and SK2-selective inhibitor, 
respectively. While SKi induced apoptosis, ROMe initiated an autophagic cell death 
in our in vitro cell models. SKi treatment induced an increase in SK1 protein levels 
in Molt-4 cells, whereas it activated the endoplasmic reticulum (ER) stress/unfolded 
protein response (UPR) pathway in Jurkat and CEM-R cells as protective mechanisms 
in a sub-population of T-ALL cells. Interestingly, we observed a synergistic effect of 
SKi with the classical chemotherapeutic drug vincristine. In addition, we reported 
that SKi affected signaling cascades implicated in survival, proliferation and stress 
response of cells. These findings indicate that SK1 or SK2 represent potential targets 
for treating T-ALL.
INTRODUCTION
The bioactive lipid sphingosine 1-phosphate (S1P) 
is implicated in many physiological and pathological 
processes such as survival, cell growth and migration 
[1]. On the contrary, its precursors, namely ceramide 
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and sphingosine, are considered pro-apoptotic and anti-
mitotic agents. As S1P, sphingosine and ceramide are 
interconvertible, it has been proposed that the balance of 
this “sphingolipid rheostat” is critical in determining cell 
death or survival [2]. S1P is formed by the phosphorylation 
of sphingosine by sphingosine kinase 1 (SK1) or 
sphingosine kinase 2 (SK2). SK1 has an important role 
in cancer [1], as demonstrated by the finding that its 
expression is upregulated at mRNA transcript and protein 
levels in numerous types of solid cancers, including lung 
cancers [3, 4] glioblastoma [5], thyroid cancer [6], and 
breast carcinoma [7, 8] 
Many studies reported that high tumor SK1 
expression is associated with increased disease 
progression, chemo-resistance and reduced patient 
survival [5, 7, 9, 10]. Furthermore, a role of SK1 has been 
recently proposed by Watson and colleagues in regulating 
the Warburg effect in prostate cancer cells [11]. 
On the other hand, the role of SK2 in regulating 
apoptosis is still a matter of debate, even though emerging 
evidence has highlighted the importance of a role for SK2 
in cancer. Some studies supported a pro-apoptotic role of 
SK2 [12], while others demonstrated that selective SK2 
inhibitors or siRNA silencing of SK2 induced cell death 
in vitro and in vivo [13, 14]. In addition, silencing of 
SK2 enhanced doxorubicin-induced apoptosis in breast 
or colon cancer cells [15]. Therefore, it appears evident 
that SKs represent a promising target for cancer therapy 
and increasing efforts are being made to develop isoform-
selective inhibitors of SKs.
T-cell acute lymphoblastic leukemia (T-ALL) 
represents a malignant disorder arising from the neoplastic 
transformation of T-cell progenitors. T-ALL accounts for 
10-15% of pediatric and 25% of adult cases [16]. The 
prognosis of pediatric T-ALL has recently improved due 
to intensified therapies, attaining more than 75% cure rates 
for children. However, pediatric T-ALL is prone to early 
relapse, and the prognosis of relapsed and primary chemo-
resistant patients is poor [16]. Hence, more efficient and 
new therapeutic strategies displaying less toxicity are now 
required. Recently, the relevance of S1P in hematological 
malignancies has been highlighted by several groups 
[17, 18]. Importantly, a link between the S1P pathway 
and major signaling pathways aberrantly activated in 
T-ALL, such as phosphatidylinositol 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) and Ras/Raf/
MEK/ERK cascades has been described [19]. For these 
reasons, we decided to analyze the possible therapeutic 
effects of two SK inhibitors in T-ALL cell lines and 
primary cells: 2-(p-hydroxyanilino)-4-(p-chlorophenyl)
thiazole (SKi), an SK1/2 inhibitor, and (R)-FTY720 
methyl ether (ROMe), a SK2-selective inhibitor [20].
We reported herein that SKi and ROMe affected 
T-ALL cell viability; however, they exerted their effects 
through different mechanisms. Indeed, we showed 
here that the SK2 selective inhibitor ROMe induced an 
autophagic cell death, while SKi induced apoptosis. 
Moreover, for the first time, we demonstrated that SKi 
activated an ER stress/UPR pathway in a sub-population 
of T-ALL cells, a signaling network induced by the 
accumulation of unfolded proteins within the ER. In 
certain T-ALL cell lines, the UPR induced by SKi was 
linked with a protective autophagic response that appeared 
to be an attempt by the cells to counteract apoptosis 
induced by SKi. Finally, we demonstrated that SKi is 
synergistic with the conventional chemotherapeutic 
agent vincristine, suggesting that combined treatment of 
established chemotherapeutic agents with SK inhibitors 
could be a feasible approach to achieve efficacy in the 
treatment of T-ALL in the clinic. These results suggest that 
SK1 or SK2 inhibition is linked with a complex network 
of cell survival and death responses. Our findings provide 
information that may open new avenues for therapeutics 
designed to induce T-ALL cell death and thereby enable 
better management of this cancer.
RESULTS
SKi displays cytotoxic effects on T-ALL cell lines 
and patient T-ALL cells
Previous studies have shown that SKi displayed 
anti-proliferative and cytotoxic effects in acute and chronic 
myeloid leukemia cell lines [21]. To determine whether 
SKi also inhibited T-ALL cell proliferation and survival, 
we performed MTT assays using Molt-4, Jurkat, CEM-S 
and the drug-resistant CEM-R cell lines. Treatment of 
these cells with increasing concentrations of SKi for 40 
h induced a reduction in cell viability with IC50 values of 
6.9, 18, and 9.4 µM in Molt-4, Jurkat and CEM-R cells 
(Figure 1A). The IC50 for CEM-S cells was not attained 
within the SKi concentration range used in this study. SKi 
also affected cell viability of primary lymphoblasts from 4 
different T-ALL pediatric patients with IC50 ranging from 
0.79 to 5.5 µM (Figure 1B). In common with the T-ALL 
cell lines, a sub-population of three of the patient T-ALL 
cells appeared more resistant to SKi. Overall, these data 
demonstrated that SKi reduced the viability of T-ALL 
cell lines and primary human patient cells. This is likely 
due to the induction of cell death as we did not detect an 
impairment of the cell cycle at any time of cell treatment 
with SKi (data not shown).
SKi promotes apoptosis in Molt-4 cell lines
In order to determine whether the decreased viability 
was related to apoptosis, Molt-4 cells were treated with a 
SKi concentration equivalent to the IC50 (6.9 µM) for 6, 
16, 24 and 40 h, after which the cells were stained with 
Annexin-V and propidium iodide (PI) and analyzed by 
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flow cytometry. Cells underwent apoptosis after 6 h of 
SKi treatment as demonstrated by the increasing presence 
of Annexin-V+/PI- and Annexin-V+/PI+ cells which reflect 
early and late apoptosis, respectively (Figure 2A). The 
presence of low levels of PI-positive only cells after 40 h 
of treatment demonstrated that cell death was mainly due 
to apoptosis.
We next measured the activation status of various 
caspases. In this regard, activation of caspase -9, -3, and 
-8, as well as cleavage of poly ADP-ribose polymerase 
(PARP) was evident in SKi-treated cells in a time-
dependent manner (Figure 2B). Transmission electron 
microscopy (TEM) analysis highlighted the presence of 
condensed apoptotic chromatin confirming apoptosis 
induction (Figure 2C). Furthermore, western blot analysis 
of LC3 protein, a widely recognized marker of autophagy, 
demonstrated that the autophagic process was not activated 
in Molt-4 cells (Figure 2D). This is consistent with the 
unchanged expression levels of Ser 2448 p-mTOR, a 
negative regulator of autophagy and whose decreased 
expression might be related to autophagy induction [22].
It has been reported that chronic exposure to SKi 
induced the proteasomal degradation of SK1 at protein 
level in solid tumor cancer cell lines [23]. Thus, we 
investigated whether a treatment of T-ALL cells with SKi 
might regulate the expression of SK1. Molt-4, Jurkat and 
CEM-R cells were treated with SKi for 40 h and SK1 
expression was measured at both transcript and protein 
levels. SK1 transcript did not significantly change in all 
three cell lines (data not shown). SKi had no effect on 
SK1 protein levels in Jurkat and CEM-R cells; however, 
SKi induced an increase in SK1 protein levels in Molt-4 
cells (Figure 2E). As high SK1 expression and S1P levels 
confer enhanced growth and survival to cells [5, 24, 25], 
the increase in SK1 protein levels could represent an 
attempt of Molt-4 cells to escape SKi-induced apoptosis. 
Indeed, a sub-population of Molt-4 cells do appear more 
resistant to high concentrations (> 5 µM) of SKi (Figure 
1A), where there is no further decline in cell viability.
Figure 1: SKi affects viability of T-ALL cell lines and primary lymphoblasts. (A) MTT assays were performed after 40 h 
of SKi treatment. Results are the mean of at least three different experiments ± s.d. Corresponding IC50 values are reported for each cell 
line in the table. The IC50 value for each data point was calculated with the appropriate software (CalcuSyn). (B) MTT assays on four 
representative patient samples treated for 24 h. n.a.: not attained.
Oncotarget7889www.impactjournals.com/oncotarget
Figure 2: SKi triggers apoptosis in Molt-4 cell line. (A) Flow cytometric analysis of Annexin-V-FITC/PI stained Molt-4 cells 
treated with SKi (6.9 µM) for 6, 16, 24 and 40 h documented a time-dependent increase in apoptotic cells with respect to untreated cells. 
(B) After SKi treatment, cells were collected, lysed and analyzed by western blotting for cleaved caspase-9, -3, and -8. (C) Molt-4 cells were 
treated with SKi (6.9 µM) for the indicated time, then processed for TEM analysis that documented apoptosis induction. Arrows point to 
condensed apoptotic chromatin. Scale bar 2 µm. (D) Western blot analysis for the autophagic marker LC3 and p-mTOR (Ser2448) in cells 
treated with SKi for the indicated times. (E) Western blot analysis for SK1 expression in T-ALL cell lines upon SKi treatment for 40 h. In 
(B) (D) and (E) 50 µg of protein was loaded for each lane. β-tubulin was used as a loading control.
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SKi induced an ER-stress-dependent autophagy 
to protect cells against apoptosis in Jurkat and 
CEM-R cell lines
We next assessed the effects of SKi on the death 
of Jurkat and CEM-R cell lines. SKi treatment of these 
cells not only augmented the percentage of early and 
late apoptotic cells, but also induced an increase in the 
population of cells that were stained by Annexin-V–/
PI+ (Figure 3A and Figure 3B). Consequently, we 
analyzed whether SKi activated apoptotic and autophagic 
pathways in these cells. SKi activated apoptosis in Jurkat 
and CEM-R cells as demonstrated by the cleavage of 
caspase-3, -9, -8, -2, and PARP. Interestingly, in Jurkat and 
CEM-R cells, caspase-3 and caspase-9 cleavage peaked at 
6 h and was less evident or absent after longer exposure 
to SKi. Therefore, consistent with the effect of SKi on cell 
viability, these results supported the possibility that a sub-
population of Jurkat and CEM-R cells were resistant to 
apoptotic death as evident in Figure 1A at concentrations 
> 5 µM SKi, where there is no further decline in cell 
viability.
Interestingly, there was a delayed conversion from 
LC3 I to the lipidated form LC3 II at 24 and 40 h after 
addition of SKi to the cells. These findings suggested the 
activation of autophagy at later time points. Of note, there 
was a concomitant down-regulation of p-mTOR (Ser2448) 
that might release the inhibition of the autophagic process 
that can be exerted by the mTORC1 complex (Figure 3C) 
[26]. Therefore, the autophagic response occurred after 
the peak of apoptotic response. This is consistent with an 
adaptive protective mechanism that could account for the 
resistance to SKi in a sub-population of the T-ALL cells.
We also investigated the effects of SKi (40 h 
treatment) on the cellular structure and organization 
in Jurkat and CEM-R cells, using TEM analysis. SKi 
caused an enlargement of the endoplasmic reticulum (ER) 
compared to controls, that is characteristic of ER stress, 
and the appearance of autophagosomes containing cell 
components (Figure 3D).
It is known that caspase-2 is implicated in the 
modulation of cell death induced by DNA damage, ER 
stress, and mitotic catastrophe [27]. It has also been 
documented that a relationship exists between ER stress 
and caspase-2 activation in human multiple myeloma 
cells [28]. In addition, it has been recently reported that 
ER stress and UPR activation drives apoptosis in T-ALL 
cell lines [29]. The cleavage of caspase-2 and an enlarged 
ER observed by TEM, prompted us to investigate if an 
UPR in Jurkat and CEM-R cells is initiated in response 
to SKi. We therefore analyzed the expression levels of 
several ER stress/UPR hallmarks, such as IRE1α, GRP78 
(BIP), p-eIF2α and CHOP. SKi induced a substantial 
increase in the expression of these UPR proteins between 
24 and 40 h, which confirmed the induction of ER stress/
UPR. The time course of ER stress was post-apoptotic 
and correlated with autophagy (Figure 4A). Interestingly, 
CEM-S cells, which were less sensitive to SKi, displayed 
a stronger induction of IRE1α, and CHOP than CEM-R 
cells (Supplementary Figure 1). In contrast, Molt-4 cells, 
did not display any significant induction of ER stress/UPR 
hallmarks (Supplementary Figure 2).
Several lines of evidence have recently suggested a 
pro-survival effect of ER stress/UPR signaling pathway 
and autophagy in cancer [30, 31] while other studies 
support a tumor-suppressive role of UPR [32, 33]. In 
order to establish whether autophagy was a protective 
mechanism involved in maintaining ER homeostasis 
that subsequently promotes cancer cells survival, we 
treated Jurkat and CEM-R cell lines with chloroquine, an 
inhibitor of autophagy [34]. Treatment with increasing 
concentrations of chloroquine had little effect on cell 
viability after 40 h of incubation, whereas the combination 
of chloroquine (at the fixed concentration of 20 µM) and 
increasing concentrations of SKi induced a significant 
decrease in cell viability (Figure 4B). These findings 
indicated that the UPR/autophagic response is likely to be 
a protective response that might account for the escape of 
a sub-population of cells from SKi-induced death.
SKi modulates signaling pathways involved in 
survival, proliferation and stress response
Many studies have shown that drugs targeting the 
S1P pathway can modulate crucial pro-survival signaling 
cascades such as PI3K/Akt/mTOR and Ras/Raf/MEK/
ERK [23, 35, 36]. In addition, S1P is linked to cancer cell 
responses to stress such as stress-activated protein kinase/
Jun-amino-terminal kinase (SAPK/JNK) and MAPK 
p38 networks [37]. Thus, we investigated whether SKi 
treatment affected these signaling pathways in T-ALL cell 
lines. Treatment of cells with SKi resulted in a decrease in 
the phosphorylation of Akt at both threonine 308 (Thr308) 
and serine 473 (Ser473) residues in Molt-4 cells. Indeed, 
ceramide, which might accumulate as a consequence of 
SK inhibition, has been shown to cause dephosphorylation 
of Akt, possibly via activation of PP2A [38]. However, 
SKi did not affect the phosphorylation of mTORC1 
downstream targets S6 ribosomal protein (S6RP) and 
eukaryotic translation initiation factor (eIF)-4E-binding 
protein 1 (4EBP1) (Figure 5A). SKi treatment reduced the 
phosphorylation of Akt only at the Thr308 in Jurkat cells, 
while CEM-R cells were resistant to modulation of Akt 
phosphorylation by SKi. Interestingly, the phosphorylation 
of JNK was markedly increased by SKi in Jurkat and 
CEM-R cells and indicated that these cells are under 
stress. p38 MAPK signaling was not affected in all the 
three cell lines. However, the Ras/Raf/MEK/ERK cascade 
in Jurkat cell was profoundly reduced by treatment with 
SKi (Figure 5A), in agreement with others [23, 35].
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Figure 3: SKi treatment induces apoptosis and autophagy in Jurkat and CEM-R cells. (A-B) Flow cytometric analysis of 
Annexin-V-FITC/PI staining in Jurkat and CEM-R cells, respectively. Cells were treated with SKi for 6, 16, 24, 40 h at the relative IC50. 
(C) Western blot analysis for apoptotic markers (caspase-3, -9, -8, -2 and PARP), autophagy marker (LC3) and p-mTOR (Ser2448). Protein 
(50 µg) was loaded for each lane.β-tubulin was used as a loading control. (D) Jurkat and CEM-R cell lines were treated with SKi for 40 
h, and then TEM analysis was performed. Apoptotic features such as chromatin condensation (see arrows) and autophagic features such 
as vacuoles and autophagosomes (indicated by the arrowhead) were visible in Jurkat cells. Scale bar 2 µm; detail of autophagic vacuoles 
scale bar 1 µm. 
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Therefore, these findings demonstrated that SKi 
perturbed different signaling pathways which play crucial 
role in leukemogenesis [39], and this might provide a 
mechanistic explanation for the ability of SKi to induce 
apoptosis.
To establish whether our findings are relevant 
to human T-ALL, we performed experiments on 
lymphoblasts from T-ALL patients. Cells were treated 
with 10 µM SKi for 24 h and the status of the PI3K/Akt/
mTOR signaling pathway was assessed. In agreement with 
the findings in T-ALL cell lines, SKi induced a decrease in 
the phosphorylation of Akt on both Thr308 and Ser473, as 
well as a decrease of p-S6RP levels (Figure 5B). SKi also 
induced apoptosis in T-ALL lymphoblasts as evidenced 
by Annexin-V/PI staining and flow cytometric analysis of 
cleaved caspase-3 (Figure 5C). 
SKi synergizes with chemotherapeutic drugs
The ability of a sub-population of T-ALL cells 
to escape apoptosis in response to SKi prompted us 
to evaluate whether treatment of cells with SKi could 
potentiate the effect of established anti-cancer agents 
or vice versa to circumvent this problem. We used 
doxorubicin and vincristine (VCR), two drugs currently 
in use for treating T-ALL patients [40]. Molt-4, Jurkat 
and CEM-R cells were incubated for 40 h with increasing 
concentrations of SKi alone (0.1-10 µM) or with SKi (0.1-
10 µM) in combination with increasing concentrations of 
VCR (1.0-100 nM). There was no observed synergistic 
effect between SKi and VCR in CEM-R cells as well as 
between SKi and doxorubicin at the concentrations we 
used in the three cell lines (data not shown). However, 
Figure 4: SKi induces autophagy as a consequence of ER stress/UPR activation in Jurkat and CEM-R cells. (A) Western 
blot analysis for ER stress/UPR hallmarks in Jurkat and CEM-R cells treated with SKi for short (4 and 6 h) and long times (24 and 40 h). 
(B) MTT assays of T-ALL cell lines treated for 40 h with increasing concentration of chloroquine (Chlor), SKi, or increasing concentration 
of SKi with chloroquine (20 µM). Results are the mean of at least three different experiments ± s.d.
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a strong synergism between SKi and vincristine was 
detected in Molt-4 and Jurkat cells. This occurred at 
concentrations of vincristine ranging from 5 to 10 nM 
in both cell lines (Figure 6A). Of note, the combination 
index (CI) analysis revealed that synergism occurred at 
concentrations of SKi that were significantly lower than its 
respective IC50 (synergism at 0.5 and 1 µM of SKi in Molt-
4 and Jurkat cells), suggesting that vincristine sensitized 
T-ALL cells to SKi.
ROMe causes autophagic cell death in T-ALL cell 
lines
Despite the controversial role of SK2 in apoptosis 
and cell fate, there is mounting evidence that SK2 
is implicated in cancer. Indeed, several groups have 
described the anti-cancer activity of different SK2-
selective inhibitors and SK2 siRNA in many types of 
tumors [13, 14, 20, 41]. Hence, we examined the effect 
of the SK2 inhibitor ROMe on the viability of T-ALL cell 
Figure 5: Effect of SKi on the phosphorylation status of signaling pathways controlling survival, proliferation. and 
stress response. (A) Molt-4, Jurkat and CEM-R cells were treated with SKi for 40 h. Then, cells were collected, lysed, and analyzed by 
western blotting. Protein (50 µg) was loaded in each lane.β-tubulin was used as a loading control. (B-C) Primary cells from T-ALL patients 
were treated with SKi (10 µM) for 24 h, stained with various antibodies or Annexin-V/PI and subjected to cytometric analysis.
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lines. We incubated cells with increasing concentrations 
of ROMe for 40 h. ROMe induced a reduction in cell 
viability that was concentration-dependent and with 
IC50 values of 8.8 µM for Molt-4 and CEM-R, 9.2 µM 
for CEM-S, and 10.1 µM for Jurkat cells (Figure 7A). 
Moreover, ROMe induced a complete reduction in cell 
viability suggesting that the cells are unable to mount a 
resistance response to this SK2 inhibitor.
To understand the mechanism of action of the 
drug, we treated Molt-4, Jurkat and CEM-R cells with a 
ROMe concentration equivalent to the IC50 for 4, 6, 24 
and 40 h and then analyzed the effect on apoptotic and 
autophagic pathways. Interestingly, the autophagic process 
was activated in a sustained manner, as evidenced by the 
accumulation of lipidated LC3-II (Figure 7B). Treatment 
of cells with ROMe also induced cleavage of caspase-3, 
-8 and -9, which peaked at 4 and 6 h, suggesting that 
apoptosis is activated only at very early time-points and 
the major cellular death is triggered by other mechanisms. 
Consequently, TEM analysis was performed on the three 
cell lines which revealed the typical autophagic features in 
Molt-4, Jurkat and CEM-R cells (Figure 7C). In addition, 
we demonstrated that, in all the three cell lines , exposure 
to the autophagic inhibitors chloroquine, 3-methyladenine 
(3-MA) and bafilomycin A1 markedly reduced the effect 
of ROMe on cell viability (Figure 8A), whereas treatment 
with the pan-caspase inhibitor Z-VAD-FMK does not 
affect it (Figure 8A), suggesting that autophagy is the 
major mechanism of cell death. 
We next analyzed ER stress/UPR hallmarks. We 
Figure 6: SKi and vincristine synergize in Molt-4 and Jurkat cells. MTT assays of Molt-4 and Jurkat cells treated for 40 h with 
increasing concentrations of SKi and/or vincristine (VCR). The combined treatment resulted in strong synergism (CI < 0.3). Data represent 
the mean of at least three independent experiments ± s.d.
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observed that these markers associated with autophagic 
survival, did not exhibit any significant modulation, 
suggesting that the UPR response is specific to SKi, and 
possibly SK1 inhibition (Figure 8B) and that autophagy in 
response to ROMe represents a cellular death mechanism. 
Finally, we investigated whether ROMe modulates 
signaling networks that regulate cell survival. In contrast 
with SKi, ROMe did not affect any of the signaling 
pathways analyzed with the exception of a reduction in 
the levels of phosphorylated ERK in Jurkat and CEM-R 
cells (Figure 8C).
DISCUSSION
A growing body of evidence indicates that 
sphingolipids play a critical role in regulating several 
physiological and pathophysiological processes, 
including cancer. Indeed, S1P is found in higher levels 
in many tumors compared with normal tissue and SK1 
overexpression is associated with a poor prognosis in solid 
Figure 7: ROMe induces autophagy in Molt-4, Jurkat and CEM-R cells. (A) MTT assays of Molt-4, Jurkat, CEM-R, and 
CEM-S cells treated with increasing concentrations of ROMe for 40 h. The results are the mean of three different experiments ± s.d. The 
table shows IC50 values of each cell line. (B) Western blot analysis documented that incubation with ROMe for 4, 6, 24, and 40 h activated 
caspases only after very short times of drug incubation, and a sustained autophagy in Molt-4, Jurkat and CEM-R cell lines. Cells were 
treated with ROMe at a concentration which corresponds to the IC50. Protein (50 µg) was loaded for each lane.β-tubulin was used as a 
loading control. (C) TEM analysis of CEM-R cells documented the presence of large cytoplasmic vacuoles containing various degraded 
organelles (arrow). Scale bar 2 µm.
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and hematological malignancies [1, 42]. Many efforts 
are being devoted to the development of new molecules 
targeting sphingolipid-based pathways. In recent years, 
many compounds have been synthesized and tested in in 
vitro and in vivo models of different type of cancers.
Among the chemical inhibitors that are selective 
for SK2 over SK1, the best are ABC294640 [13], ROMe 
[20], K145 [41], SLR080811 [43] and F02 [44], which 
have moderate potency, with Ki values in the range 
of ~1-10 μM. Moreover, treatment of MCF-7 breast 
cancer cells with ROMe prevented actin enrichment 
into lamellipodia in response to S1P, suggesting that 
migratory and metastatic responses of cancers cells might 
be dependent on SK2 [20]. In addition, ABC294640 
suppressed the proliferation of several tumor cell lines, 
and inhibited tumor cell migration associated with the loss 
of actin microfilaments [13]. ABC294640 also displayed 
significant in vivo activity and inhibited tumor progression 
Figure 8: ROMe induces an autophagic cell death without the activation of the ER stress/UPR pathway. (A) Inhibition of 
autophagy by chloroquine (Chlor) (20 µM), bafilomycin A1 (baf A1) (5 nM), or 3-MA (200 µM) [60] impairs the cytotoxic effect of ROMe 
(40 h). Inhibition of apoptosis through Z-VAD-FMK (20 µM) does not affect ROMe-induced cell death. Cell viability was assessed by 
MTT assay on Molt-4, Jurkat, and CEM-R cells. (B) Cells were treated with ROMe for 4, 6, 24 and 40 h, collected, lysed and subjected to 
western blotting for ER stress/UPR markers. Protein (50 µg) was loaded for each lane.β-tubulin was used as a loading control. (C) Molt-4, 
Jurkat and CEM-R were treated with ROMe for 40 h and western blot analysis was performed. ROMe does not interfere with the analyzed 
signaling pathways, with the exception of a down-regulation of Raf/MEK/ERK in Jurkat cells. 
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in mice with mammary adenocarcinoma xenografts [13]. 
More recent studies have demonstrated that ABC294640 
induced autophagic death in A-498 kidney, PC-3 prostate 
and MDA-MB-231 breast cancer cells [36].
Despite excellent progress in the treatment of 
T-ALL, with most promising results obtained in pediatric 
patients, an efficient cure is still challenging. Mortality 
from T-ALL is still 25% for children and 40-50% for adults 
[16]. For this reason, innovative approaches that are more 
effective and display less toxicity, especially for patients 
who develop resistance to traditional chemotherapeutic 
drugs, are needed. 
In this study, we investigated the therapeutic 
potential of two SK inhibitors in pre-clinical settings of 
T-ALL. In particular, we tested SKi and ROMe, that target 
SK1/SK2 and SK2, respectively, in T-ALL cell lines and 
primary cells. We demonstrated that both inhibitors induce 
a reduction in the cell viability with IC50 values that were 
comparable, but they exerted their effects through different 
mechanisms. 
SKi initiated an apoptotic cell death in Molt-4, 
Jurkat, and CEM-R cell lines, as well as in lymphoblasts 
from T-ALL patients, in agreement with other studies 
[3]. Although an apoptotic process was initiated upon 
SKi treatment, a sub-population of T-ALL cell lines 
seems to escape death using different strategies. A ‘non-
oncogene addiction’ has been proposed for SK1, as it has 
been found over-expressed in many types of solid tumors 
[42]. In the present study, we reported that SKi induced 
increased expression of SK1 in Molt-4 cells. Since we 
know from cytometric analysis that, after 40 h, a large 
amount of cells die, it is possible that the remaining viable 
cells represented a sub-population that are more resistant 
to apoptosis owing to the adaptive increase in SK1 
expression in these cells. This hypothesis is supported by 
the negligible induction of ER stress/UPR pathway in this 
cell line.
Jurkat and CEM-R cells behaved differently. We 
did not observe any increased SK1 expression in these 
cell lines. However, after 24 h of SKi treatment an ER 
stress/UPR pathway was initiated. UPR is a highly 
conserved stress pathway which is considered to be an 
adaptive response for safeguarding cell survival and that 
is aimed at restoring ER homeostasis [45]. It is known 
that the ER stress/UPR pathway is a potent stimulus of 
autophagy which represents an attempt by the cells to 
counteract the ER stress [30, 31].We report here that 
SKi induced the activation of an ER stress/UPR-induced 
autophagy in Jurkat and CEM-R cell lines. TEM analysis 
demonstrated the occurrence of alterations in ER structural 
organization and double membrane autophagosomes in the 
cytoplasm. These findings are consistent with an ongoing 
autophagic process. Consistently, LC3 conversion, another 
bona fide autophagic marker, was evident after 24 h of 
the drug treatment. Of interest, in Jurkat and CEM-R, 
but not in Molt-4 cell lines, we found a reduction of 
the phosphorylation status of mTOR (at Ser 2448) 
which is a negative regulator of autophagy and whose 
decreased expression might be associated with autophagy. 
Accordingly, treatment of Jurkat and CEM-R cells with 
chloroquine, an inhibitor of autophagy, potentiated rather 
than prevented cell death, suggesting a cyto-protective role 
of autophagy. 
We also demonstrated that a combination of SKi 
with vincristine, a drug commonly used in T-ALL therapy, 
was synergistic in promoting T-ALL cell death. Therefore, 
SKi could potentiate the effect of chemotherapeutic drugs 
by surmounting the protective mechanisms, such as 
autophagy that confer resistance to SKi.
Interestingly, we reported that SKi treatment 
perturbed signaling cascades implicated in survival, 
proliferation and stress response of cells in our in vitro 
models. In particular, SKi treatment caused a reduction in 
p-Akt in Molt-4 and Jurkat cells. SKi could also modulate 
the Ras/Raf/MEK/ERK pathway, which is constitutively 
activated in Jurkat cells. This caused a marked decrease 
in p-ERK (Thr202/Tyr204) levels. In addition, there is a 
strong increase in p-JNK (Thr183/Tyr185) levels in Jurkat 
and CEM-R cells, suggesting that these cells are under a 
severe stress response. In fact, it is known that an increase 
in SAPK/JNK signaling pathway is a common response 
to many forms of stress, including ER stress (IRE1α-
induced) [30].
We also assessed the effect of ROMe, a selective 
SK2 inhibitor, on T-ALL cell line survival. Recently, it 
was shown that the inhibition of SK2 activated autophagy 
in solid tumors [11, 13]. Despite an initial cleavage of 
caspases upon treatment of cells with ROMe, we found 
that ROMe induced a cytotoxic response through the 
activation of an autophagic process, as demonstrated 
by TEM analysis and increased LC3 processing. This 
hypothesis was then confirmed by treatment with the 
autophagic inhibitors chloroquine, bafilomycin A1 and 
3-MA that were able to block the effect of ROMe, whereas 
the pan-caspase inhibitor Z-VAD-FMK was not. The 
concomitant cleavage of caspases, detected only after 4 
and 6 h of ROMe exposure, is not surprising, given the 
strict interconnection between apoptosis and autophagy, 
as reviewed by many authors [46-48].
Notably, ROMe did not activate the ER stress/UPR 
pathway and did not perturb several signaling pathways 
including PI3K/Akt/mTOR, SAPK/JNK, and p38 MAPK. 
These data demonstrated that ROMe drives cell death 
through different mechanisms compared with SKi. More 
importantly, our findings demonstrated different cellular 
outcomes of autophagy that might be determined by the 
presence or absence of UPR and mTOR regulation.
In addition, the ability of ROMe to completely 
reduce T-ALL cell viability suggested that, in our in vitro 
models, no adaptive protective mechanisms are activated 
by ROMe. This might suggest a more compelling 
therapeutic utility for SK2 selective inhibition over and 
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above combined SK1 and SK2 inhibition in T-ALL cells.
In conclusion, the data presented here, strongly 
suggest that SK1 or SK2 inhibition is linked with a 
complex network of cell survival and death responses 
in T-ALL cells. These findings also provide useful 
information that could be used for designing novel SK2 
inhibitors aimed at eradicating T-ALL cells and thereby 
enabling a better management of this type of cancer.
MATERIALS AND METHODS
Chemicals
Shingosine kinase (SKi) (2-(p-hydroxyanilino)-4-
(p-chlorophenyl)thiazole) was purchased by Calbiochem 
(EMD Chemicals, San Diego, CA, USA). Vincristine and 
doxorubicin were from Sigma-Aldrich (St. Louis, MO, 
USA). Bafilomycin A1, 3-methyladenine (3-MA), and 
Z-VAD-FMK were from Enzo Life Science (Plymouth 
Meeting, PA, USA). ROMe ((R)-FTY720 methyl ether) 
was synthesized according to Lim and colleagues [20]. 
Antibody to SK1 was as reported elsewhere [7]. For 
western blot analysis, primary antibodies were from Cell 
Signaling Technology (Danvers, MA, USA). For flow 
cytometric analysis, phycoerythrin (PE)-conjugated anti-
cleaved caspase-3 (Asp175) was from Cell Signaling 
Technology. p-Akt and p-S6RP levels were performed as 
reported elsewhere [49, 50].
Cell culture and primary samples
The T-ALL cell lines Molt-4, Jurkat, CEM-R (CEM 
VBL100, drug-resistant cells overexpressing 170-kDa 
P-glycoprotein [51], and CEM-S were grown in RPMI 
1640 supplemented with 10% heat-inactivated fetal bovine 
serum (FBS). Samples from T-ALL pediatric patients were 
obtained with informed consent according to Institutional 
guidelines and isolated using Ficoll-Paque (Amersham 
Biosciences, Little Chalfont, UK) and were grown in 
complete medium (RPMI 1640 supplemented with 20% 
FBS, and ITS (insulin-transferrin-sodium selenite). 
MTT assay
Cell viability was assessed using MTT 
(3-[4,5-Dimethylthythiazol-2-yl]-2,5- Diphenyltetrazolium 
Bromide) assays as previously described [52, 53]. In 
particular, T-ALL patient lymphoblasts (1 x 106 cells/
ml) were cultured in triplicate in flat-bottomed 96-well 
plates at 37°C with 5% CO2. Cultures were carried out 
for 48 and 96 h. Results were statistically analyzed by 
GraphPadPrism Software (GraphPad Software Inc., San 
Diego, CA, USA). 
Annexin-V/PI staining
Analysis of cell viability and apoptosis was carried 
out after drug treatment by dual staining with Annexin 
V-FITC and propidium iodide (PI) as reported elsewhere 
[54]. Cells were analyzed on a FC500 flow cytometer 
(Beckman Coulter, Miami, FL, USA).
Western Blot analysis
Western blot analysis was carried out by standard 
methods, as previously reported [55, 56]. Analysis with 
an antibody to β-actin or β-tubulin demonstrated equal 
protein loading. For SK1 analysis, whole cell extracts 
were prepared as described [11].
TEM analysis
TEM analysis was performed according to standard 
techniques, as previously described [57], using a Philips 
CM10 (Philips, Eindhoven, The Netherlands) TEM. 
Images were recorded on a Megaview III digital camera 
(Olympus, Tokyo, Japan).
Combined drug effect analysis
The combination effect and a potential synergy 
were evaluated from quantitative analysis of dose-effect 
relationships as described previously [58, 59]. For each 
combination experiment, a combination index (CI) number 
was calculated using the Biosoft CalcuSyn software. This 
method of analysis generally defines CI values of 0.9 
to 1.1 as additive, 0.3 to 0.9 as synergistic, and <0.3 as 
strongly synergistic, whereas values >1.1 are considered 
antagonistic.
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